Hansa Biopharma    

Accelerated Bookbuild Offering

SEK 1.11 billion
Joint Bookrunner
;

Hansa Biopharma

Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Hansa Biopharma’s Capital Increase of SEK 1.11 billion

Transaction highlights

  • Capital increase of 4,447,345 shares, representing c. 9.9% of the issued share capital of Hansa Biopharma after the launch, at a price of SEK 250.00 per share, representing a discount of 8.5% to the last closing price
  • The transaction was launched on the back of the positive CHMP opinion for Hansa Biopharma’s lead product candidate imlifidase in kidney transplantation in highly sensitized patients, as well as a partnership announcement with Sarepta Therapeutics to use Hansa’s unique IgG antibody-cleaving enzyme technology alongside gene therapy in select indications
  • Gross proceeds amounted to SEK 1.11 billion/ USD 121 million, which will be used to continue the development and expansion of the Company’s R&D pipeline as well as to fund the potential launch and commercialization of imlifidase in kidney transplantation
  • The share issue was multiple times covered with significant support from existing shareholders and wall-crossed accounts, including Redmile Group, Consonance Capital, HBM Healthcare Investments and Fonden TIN Ny Teknik
  • Kempen & Co has been supporting the Company in its outreach to specialist investors since 2018
  • Since the beginning of 2020, Kempen & Co has already executed 13 transactions for European life sciences companies. 

Company description

Hansa Biopharma is a clinical-stage biotechnology company leveraging its proprietary IgG antibody- cleaving enzyme technology platform to develop treatments for enabling transplantations, rare autoimmune conditions, transplant rejection and cancer. On 25 June, the Company announced a positive CHMP opinion for its lead product candidate imlifidase, which recommends conditional approval of imlifidase for kidney transplantation in highly sensitized patients in Europe. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. On 02 July, the Company announced a partnership with Sarepta Therapeutics, a leader within gene therapy focusing on muscular dystrophies,  allowing them to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today are not eligible for these breakthrough therapies due to pre-existing neutralising antibodies. As part of this partnership, Hansa will receive a USD 10 million upfront payment and potential development, regulatory and sales milestone payments up to USD 397.5 million, as well as mid-teens tiered royalties on Sarepta’s gene therapy sales. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the United States.

Relevant transactions Kempen & Co Life Sciences & Healthcare

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Co-Manager in the USD 49.0 million US Public Offering by Centogene
  • Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
  • Co-Manager in the USD 600 million US Public Offering by Ascendis Pharma
  • Financial advisor in the USD 253 million Immatics’ business combination with Arya Sciences Acquisition Corp.Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by argenx
  • Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
  • Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
  • Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
  • Lead Manager in the USD 557 million Global Offering by argenx
  • Co-Manager in the USD 79.2 million US Public Offering by Merus
  • Co-Manager in the USD 57.5 million Capital Increase by ProQR
  • Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
  • Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
  • Co-Manager in the USD 20.0 million Global Offering of Celyad
  • Co-Manager in the USD 582 million NASDAQ IPO of Genmab

Contact

Jan De Kerpel
Nadine Maalouf
Thomas ten Hoedt

Transactions